Wait, we have a special offer for you! ✋

Get your exclusive discount now

YES, get the discount! No, I'd pay the full price

Cancer Monoclonal Antibodies Market 2022 – By Monoclonal Antibody Therapies (Avastin, Herceptin, Keytruda, Opdivo, Darzalex, Perjeta), By Application (Breast Cancer, Blood Cancer, Lung Cancer, Brain Tumor, Colorectal Cancer, Cervical Cancer, Gastric Cancer), By End-User (Hospitals, Research Laboratories), And By Region, Opportunities And Strategies – Global Forecast To 2030

Cancer Monoclonal Antibodies Global Market Opportunities And Strategies To 2030: COVID 19 Growth And Change

Starting Price : $5000.00 $3500.00 | Pages : 219 | Published : June 2022 | | Format : pdf

Purchase Options
Request a Sample
Request For Discount
Customise Your Report
Item added to cart!
Request For Proposal
Request For Regional Data
FAQs

Need assistance or more information before the purchase?

Enquire Before Buying

Proud Members Of

checkslacipN checkaoirsN checkscipN
Description Table Of Contents Tables & Figures Market Insights Related Reports

Cancer Monoclonal Antibodies Market Definition

The cancer monoclonal antibodies market consists of sales of cancer monoclonal antibodies and related services by entities (organizations, sole traders and partnerships) that produce cancer monoclonal antibodies that prevent or inhibit the proliferation, maturation or survival of cancer cells. Cancer monoclonal antibodies recognize and bind to proteins in a highly selective manner. By binding specifically to proteins expressed by cancer cells they can selectively target these transformed cells and destroy them by activating the immune response or delivering cytotoxins.

Book your 30 minutes free consultation with our research experts

Contact Us

Cancer Monoclonal Antibodies Market Size

The global cancer monoclonal antibodies market reached a value of nearly $53,785.1 million in 2020, having increased at a compound annual growth rate (CAGR) of 20.47% since 2015. The global cancer monoclonal antibodies market size is expected to grow from $53,785.1 million in 2020 to $86,056.7 million in 2025 at a rate of 9.9%. The global cancer monoclonal antibodies market size is then expected to grow at a CAGR of 7.3% from 2025 and reach $122,283.7 million in 2030.    

Growth in the historic period resulted from emerging markets growth, increase in R&D expenditure, increased geriatric population, and increased preference for biological treatments. Factors that hindered the growth of the cancer monoclonal antibodies market during the historic period include low healthcare access, failures of cancer monoclonal antibodies in clinical trials, usage of surrogate endpoints in clinical trials, and pricing pressures from regulators.

Going forward, increasing prevalence of cancer, expanding global access, and rise in healthcare expenditure will drive the growth. Factors that could hinder the growth of the cancer monoclonal antibodies market in the future include high cost in development of monoclonal antibodies, and stringent regulatory guidelines.

Cancer Monoclonal Antibodies Market Drivers

The key drivers of the cancer monoclonal antibodies market include:

Increasing Prevalence Of Cancer

The rising prevalence of cancer cases across the globe is likely to contribute to the growth of the cancer monoclonal antibody market during the forecast period. According to the Union for International Cancer Control (UICC)’s GLOBOCAN 2020: New Global Cancer Data published in December 2020, the global cancer burden has risen to 19.3 million cases and 10 million cancer deaths in 2020.  According to the American Cancer Society, there were 1.7 million new cases and 0.6 million cancer deaths in 2019 in the USA.  Furthermore, according to the International Agency for Research on Cancer (IARC), globally 1 in 5 people develop cancer during their lifetime, and 1 in 8 men and 1 in 11 women die from the disease. As suggested by the new estimates, more than 50 million people are living within five years of a past cancer diagnosis.  Socio-economic risk factors and the elderly population are a major cause for increasing cancer cases, thereby driving the growth of the cancer monoclonal antibodies market.

Cancer Monoclonal Antibodies Market Restraints

The key restraints on the cancer monoclonal antibodies market include:

High Cost In Development Of Monoclonal Antibodies

The high costs involved in the development of monoclonal antibodies with advanced techniques act as a major restrain for the market due to the complex production process, expensive biological and chemical materials, and clinical trials, as well as required safety, efficacy, and quality tests. Advanced equipment is required for the large-scale production of monoclonal antibodies that encompass multiple disulfide bonds and post-translational modifications, and this equipment is expensive. Clinical efficacy is usually achieved by injecting large amounts of monoclonal antibodies into the system, which means that large quantities are required to be produced for each treatment, thus increasing the cost. Thus, the high development costs in using these advanced techniques will restrain market growth.

Cancer Monoclonal Antibodies Market Trends

Major trends influencing the cancer monoclonal antibodies market include:

Humanized Cancer Monoclonal Antibodies

Humanized antibodies are the antibodies derived from non-human species whose proteins have been modified to enhance their resemblance to natural human antibodies. The humanized antibodies can be generated through recombinant DNA methods using an appropriate vector and expression in mammalian cells.  The humanized antibody has advantages such as reduced immunogenicity, and increased serum half-life of the mAb in humans.  The first fully human therapeutic antibody, adalimumab (Humira), an anti-tumor necrosis factor a (TNFa) human antibody was approved in 2002 by the US FDA for rheumatoid arthritis.  As of December 2019, 30 fully human monoclonal antibodies and 1 fully human bispecific antibody (Lumoxiti®) have been approved for clinical use.

Technological Advancements in Gene Sequencing and Target Gene Selection

Technological advancements such as gene sequencing and target gene selection are used by pharmaceutical companies in the cancer monoclonal antibodies market. The increase in adoption of genome wide analysis, global tumour expression profiling and artificial intelligence is promoting opportunities for improved target selection and personalized medicine. Various powerful techniques such as hybridoma technology, phage display, and B-cell amplification with the help of PCR have been developed for the construction of numerous types of antibodies and antibody fragments with widespread structural modifications.  Scientists developed various hybridoma technologies, which involve the fusion of antibody-producing cells—clones of a unique antibody-producing parent cell—with immortalized myeloma tumor cells.  Combinations of tumor-targeted mAbs with ICB (Immune checkpoint blockade) have demonstrated that there are several encouraging avenues for maximizing the clinical benefit of mAb therapy.  These technologies have led to the development of highly-effective monoclonal antibodies, which are gaining widespread preference among healthcare professionals.

Opportunities And Recommendations In The Cancer Monoclonal Antibodies Market

Opportunities –The top opportunities in the cancer monoclonal antibodies market segmented by monoclonal antibody therapies will arise in the others segment, which will gain $15,622.0 million of global annual sales by 2025. The top opportunities in segment by application will arise in the other segment, which will gain $12,137 million of global annual sales by 2025. The top opportunities in segment by end user will arise in the hospitals segment, which will gain $6,302.6 million of global annual sales by 2025.  The cancer monoclonal antibodies market size will gain the most in the USA at $16,361.4 million.  

Recommendations –To take advantage of these opportunities, The Business Research Company recommends the cancer monoclonal antibodies companies to focus on humanized cancer monoclonal antibodies, invest in artificial intelligence, focus on technological advancements in gene sequencing and target gene selection, invest In R&D, focus on investment in targeted and combination therapy, expand in developed markets, focus on product innovation through strategic collaborations, set up authorized distributors and sales representatives, expand in emerging markets, provide competitively priced offerings, focus on securing long-term supply contracts with healthcare institutions, offer value-based pricing, increase visibility through SEO campaigns, participate in trade shows and events, leverage social media to maximize reach, focus on increasing awareness, partnerships with end-users, targeting hospitals and pharmacies to spread awareness.

Cancer Monoclonal Antibodies Market Segmentation

The cancer monoclonal antibodies market is segmented by monoclonal antibody therapies, by application and by end user.
By Monoclonal Antibody Therapies -
The cancer monoclonal antibodies market is segmented by monoclonal antibody therapies into:
    • a) Avastin
    • b) Herceptin
    • c) Keytruda
    • d) Opdivo
    • e) Darzalex
    • f) Perjeta
    • g) Others
The others market was the largest segment of the cancer monoclonal antibodies market segmented by monoclonal antibody therapies, accounting for 30.4% of the total in 2020. Going forward, the darzalex market is expected to be the fastest growing segment in the cancer monoclonal antibodies market segmented by monoclonal antibody therapies, at a CAGR of 17.8% during 2020-2025.
By Application -
The cancer monoclonal antibodies market is segmented by application into:
    • a) Breast Cancer
    • b) Blood Cancer
    • c) Lung Cancer
    • d) Brain Tumor
    • e) Colorectal Cancer
    • f) Cervical Cancer
    • g) Gastric Cancer
    • h) Others
The others was the largest segment of the cancer monoclonal antibodies market segmented by application, accounting for 28.7% of the total in 2020. Going forward, the others segment is expected to be the fastest growing segment in the cancer monoclonal antibodies market segmented by application, at a CAGR of 12.3% during 2020-2025.
By End-User -
The cancer monoclonal antibodies market is segmented by end-user into:
    • a) Hospitals & Clinics b) Research Laboratories c) Others
The hospitals was the largest segment of the cancer monoclonal antibodies market segmented by end user, accounting for 72.5% of the total in 2020. Going forward, the others segment is expected to be the fastest growing segment in the cancer monoclonal antibodies market segmented by end user, at a CAGR of 10.1% during 2020-2025.
By Geography- The cancer monoclonal antibodies market is segmented by geography into
    • o Asia Pacific
      • • China 
      • • India 
      • • Japan 
      • • Australia 
      • • Indonesia 
      • • South Korea 
      • o North America
      • • USA
      o South America
      • • Brazil 
      o Western Europe
      • • UK
      • • Germany
      • • France
      o Eastern Europe
      • • Russia
      o Middle East
      o Africa
North America was the largest region in the cancer monoclonal antibodies market, accounting for 47.9% of the total in 2020. It was followed by Asia Pacific, and Western Europe. Going forward, the fastest-growing regions in the cancer monoclonal antibodies market will be South America, and Africa where growth will be at CAGRs of 14.0% and 12.8% respectively. These will be followed by Middle East, and North America, where the markets are expected to grow at CAGRs of 12.1% and 10.7% respectively.

Cancer Monoclonal Antibodies Market Competitive Landscape

Major Competitors are:

  • • F. Hoffmann-La Roche Ltd
  • • Merck & Co., Inc
  • • Bristol Myers Squibb Company
  • • Johnson & Johnson
  • • Amgen Inc

    • Other Competitors Include:

  • AstraZeneca plc
  • Eli Lilly and Company
  • Pfizer Inc
  • Regeneron Pharmaceuticals Inc
  • Sanofi S.A
  • Innovent Biologics
  • Sino biological
  • Shanghai Junshi Biosciences
  • Shanghai Henlius Biotech
  • Intas bio
  • Zydus Cadila
  • Ranbaxy
  • Takeda pharmaceuticals
  • AbbVie Inc
  • Biogen Idec
  • Bayer AG
  • Novartis AG
  • BiosanaPharma
  • WuXi
  • GlaxoSmithKline
  • Teva UK Limited
  • Abbott Laboratories
  • Fujifilm
  • Procos SpA
  • BSP Pharmaceuticals
  • Genmab
  • Insysbio
  • Rani Therapeutics
  • Emisphere Technologies, Inc
  • Enteris BioPharma
  • Allena Pharmaceuticals
  • Apotex
  • Gilead Sciences
  • Eurofarma
  • Teuto Brasileiro
  • BioMarin Pharmaceutical
  • BIONOVIS BRASIL
  • Ecopharm
  • Hypermarcas
  • Ache
  • Libbs Farmaceutica
  • Julphar
  • Spimaco Addwaeih
  • Hikma Pharmaceuticals
  • Tabuk
  • Novo Nordisk
  • BBI Solutions
  • APC Pharma
  • EPICIO
  • Medical Union Pharmaceuticals
  • South Egypt Drug Industries Co. Pharmaceutical
  • Vacsera Pharma
  • Aspen Pharmacare
  • Amoun Pharmaceuticals Co Ltd
  • 54gene
  • Baxter International
  • Altis Biologics
  • Cipla
  • Medpro South Africa
  • Genzyme

      • Table Of Contents

      1. Cancer Monoclonal Antibodies Market Executive Summary

      2. Table of Contents

      3. List of Figures

      4. List of Tables

      5. Report Structure

      6. Introduction

      6.1. Segmentation By Geography

      6.2. Segmentation By Monoclonal Antibody Therapies

      6.3. Segmentation By Application

      6.4. Segmentation By End User

      7. Cancer Monoclonal Antibodies Market Characteristics

      7.1. Market Definition

      7.2. Market Segmentation By Monoclonal Antibody Therapies

      7.2.1. Avastin

      7.2.2. Herceptin

      7.2.3. Keytruda

      7.2.4. Opdivo

      7.2.5. Darzalex

      7.2.6. Perjeta

      7.2.7. Others

      7.3. Market Segmentation By Application

      7.3.1. Breast Cancer

      7.3.2. Blood Cancer

      7.3.3. Lung Cancer

      7.3.4. Brain Tumor

      7.3.5. Colorectal Cancer

      7.3.6. Brain Tumor

      7.3.7. Cervical cancer

      7.3.8. Gastric cancer

      7.3.9. Others

      7.4. Market Segmentation By End User

      7.4.1. Hospitals

      7.4.2. Research Laboratories

      7.4.3. Others

      8. Cancer Monoclonal Antibodies Market Trends And Strategies

      8.1. Product Innovation Through Strategic Collaborations

      8.2. Humanized Cancer Monoclonal Antibodies

      8.3. Investment in Artificial Intelligence

      8.4. Technological Advancements in Gene Sequencing and Target Gene Selection

      8.5. R&D Investments

      8.6. Investment in Targeted and Combination Therapy

      9. Impact Of COVID-19 On The Cancer Monoclonal Antibodies Market

      9.1. Introduction

      9.2. Supply Chain Issues

      9.3. Clinical Trial Delays

      9.4. Impact On Major Players

      9.5. Future Outlook

      10. Global Cancer Monoclonal Antibodies Market Size And Growth

      10.1. Market Size

      10.2. Historic Market Growth, 2015 – 2020, Value ($ Million)

      10.2.1. Drivers Of The Market 2015 – 2020

      10.2.2. Restraints of The Market 2015 – 2020

      10.3. Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      10.3.1. Drivers Of The Market 2020 – 2025

      10.3.2. Restraints On The Market 2020 – 2025

      11. Global Cancer Monoclonal Antibodies Market Segmentation

      11.1. Global Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      11.2. Global Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      11.3. Global Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      12. Cancer Monoclonal Antibodies Market, Regional And Country Analysis

      12.1. Global Cancer Monoclonal Antibodies Market, By Region, Historic and Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      12.2. Global Cancer Monoclonal Antibodies Market, By Country, Historic and Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      13. Asia-Pacific Cancer Monoclonal Antibodies Market

      13.1. Asia-Pacific Cancer Monoclonal Antibodies Market Overview

      13.1.1. Region Information

      13.1.2. Market Information

      13.1.3. Background Information

      13.1.4. Government Initiatives

      13.1.5. Regulatory Bodies

      13.1.6. Regulations

      13.1.7. Major Associations

      13.1.8. Taxes Levied

      13.1.9. Corporate Tax Structure

      13.1.10. Investments

      13.1.11. Major Companies

      13.2. Asia-Pacific Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

      13.3. Asia-Pacific Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      13.4. Asia-Pacific Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      13.5. Asia-Pacific Cancer Monoclonal Antibodies Market: Country Analysis

      13.6. China Cancer Monoclonal Antibodies Market

      13.7. China Cancer Monoclonal Antibodies Market Overview

      13.7.1. Region Information

      13.7.2. Market Information

      13.7.3. Background Information

      13.7.4. Government Initiatives

      13.7.5. Regulatory Bodies

      13.7.6. Regulations

      13.7.7. Major Associations

      13.7.8. Taxes Levied

      13.7.9. Corporate Tax Structure

      13.7.10. Investments

      13.7.11. Major Companies

      13.8. China Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

      13.9. China Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      13.10. China Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      13.11. India Cancer Monoclonal Antibodies Market

      13.12. India Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

      13.13. India Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      13.14. India Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      13.15. Japan Cancer Monoclonal Antibodies Market

      13.16. Japan Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

      13.17. Japan Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      13.18. Japan Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      13.19. Australia Cancer Monoclonal Antibodies Market

      13.20. Australia Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

      13.21. Australia Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      13.22. Australia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      13.23. Indonesia Cancer Monoclonal Antibodies Market

      13.24. Indonesia Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

      13.25. Indonesia Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      13.26. Indonesia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      13.27. South Korea Cancer Monoclonal Antibodies Market

      13.28. South Korea Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

      13.29. South Korea Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      13.30. South Korea Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      14. Western Europe Cancer Monoclonal Antibodies Market

      14.1. Western Europe Cancer Monoclonal Antibodies Market Overview

      14.1.1. Region Information

      14.1.2. Market Information

      14.1.3. Background Information

      14.1.4. Government Initiatives

      14.1.5. Regulations

      14.1.6. Regulatory Bodies

      14.1.7. Major Associations

      14.1.8. Taxes Levied

      14.1.9. Corporate Tax Structure

      14.1.10. Investments

      14.1.11. Major Companies

      14.2. Western Europe Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

      14.3. Western Europe Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      14.4. Western Europe Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      14.5. Western Europe Cancer Monoclonal Antibodies Market: Country Analysis

      14.6. UK Cancer Monoclonal Antibodies Market

      14.7. UK Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

      14.8. UK Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      14.9. UK Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      14.10. Germany Cancer Monoclonal Antibodies Market

      14.11. Germany Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

      14.12. Germany Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      14.13. Germany Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      14.14. France Cancer Monoclonal Antibodies Market

      14.15. France Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

      14.16. France Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      14.17. France Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      15. Eastern Europe Cancer Monoclonal Antibodies Market

      15.1. Eastern Europe Cancer Monoclonal Antibodies Market Overview

      15.1.1. Region Information

      15.1.2. Market Information

      15.1.3. Background Information

      15.1.4. Government Initiatives

      15.1.5. Regulatory Bodies

      15.1.6. Regulations

      15.1.7. Major Associations

      15.1.8. Taxes Levied

      15.1.9. Corporate Tax Structure

      15.1.10. Investments

      15.1.11. Major Companies

      15.2. Eastern Europe Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

      15.3. Eastern Europe Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      15.4. Eastern Europe Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      15.5. Eastern Europe Cancer Monoclonal Antibodies Market: Country Analysis

      15.6. Russia Cancer Monoclonal Antibodies Market

      15.7. Russia Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

      15.8. Russia Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      15.9. Russia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      16. North America Cancer Monoclonal Antibodies Market

      16.1. North America Cancer Monoclonal Antibodies Market Overview

      16.1.1. Region Information

      16.1.2. Market Information

      16.1.3. Background Information

      16.1.4. Government Initiatives

      16.1.5. Regulations

      16.1.6. Regulatory Bodies

      16.1.7. Major Associations

      16.1.8. Taxes And Duties

      16.1.9. Corporate Tax Structure

      16.1.10. Investments

      16.1.11. Major Companies

      16.2. North America Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

      16.3. North America Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      16.4. North America Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      16.5. North America Cancer Monoclonal Antibodies Market: Country Analysis

      16.6. USA Cancer Monoclonal Antibodies Market

      16.7. USA Cancer Monoclonal Antibodies Market Overview

      16.7.1. Region Information

      16.7.2. Market Information

      16.7.3. Background Information

      16.7.4. Government Initiatives

      16.7.5. Regulatory Bodies

      16.7.6. Regulations

      16.7.7. Major Associations

      16.7.8. Taxes Levied

      16.7.9. Corporate Tax Structure

      16.7.10. Investments

      16.7.11. Major Companies

      16.8. USA Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

      16.9. USA Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      16.10. USA Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      17. South America Cancer Monoclonal Antibodies Market

      17.1. South America Cancer Monoclonal Antibodies Market Overview

      17.1.1. Region Information

      17.1.2. Market Information

      17.1.3. Background Information

      17.1.4. Government Initiatives

      17.1.5. Regulations

      17.1.6. Regulatory Bodies

      17.1.7. Major Associations

      17.1.8. Taxes And Duties

      17.1.9. Corporate Tax Structure

      17.1.10. Investments

      17.1.11. Major Companies

      17.2. South America Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

      17.3. South America Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      17.4. South America Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      17.5. South America Cancer Monoclonal Antibodies Market: Country Analysis

      17.6. Brazil Cancer Monoclonal Antibodies Market

      17.7. Brazil Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

      17.8. Brazil Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      17.9. Brazil Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      18. Middle East Cancer Monoclonal Antibodies Market

      18.1. Middle East Cancer Monoclonal Antibodies Market Overview

      18.1.1. Region Information

      18.1.2. Market Information

      18.1.3. Background Information

      18.1.4. Government Initiatives

      18.1.5. Regulations

      18.1.6. Regulatory Bodies

      18.1.7. Major Associations

      18.1.8. Taxes Levied

      18.1.9. Corporate Tax Structure

      18.1.10. Investments

      18.1.11. Major Companies

      18.2. Middle East Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

      18.3. Middle East Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      18.4. Middle East Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      19. Africa Cancer Monoclonal Antibodies Market

      19.1. Africa Cancer Monoclonal Antibodies Market Overview

      19.1.1. Region Information

      19.1.2. Market Information

      19.1.3. Background Information

      19.1.4. Government Initiatives

      19.1.5. Regulations

      19.1.6. Regulatory Bodies

      19.1.7. Major Associations

      19.1.8. Taxes And Duties

      19.1.9. Corporate Tax Structure

      19.1.10. Investments

      19.1.11. Major Companies

      19.2. Africa Cancer Monoclonal Antibodies Market, Historic Market Growth, 2015 – 2020, Value ($ Million)

      19.3. Africa Cancer Monoclonal Antibodies Market, Forecast Market Growth, 2020 – 2025, 2030F, Value ($ Million)

      19.4. Africa Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, Value ($ Million)

      20. Global Cancer Monoclonal Antibodies Market Competitive Landscape

      20.1. Company Profiles

      20.2. F. Hoffmann-La Roche Ltd

      20.2.1. Company Overview

      20.2.2. Products And Services

      20.2.3. Business Strategy

      20.2.4. Financial Overview

      20.3. Merck & Co., Inc.

      20.3.1. Company Overview

      20.3.2. Products And Services

      20.3.3. Business Strategy

      20.3.4. Financial Overview

      20.4. Bristol Myers Squibb Company

      20.4.1. Company Overview

      20.4.2. Products And Services

      20.4.3. Business Strategy

      20.4.4. Financial Overview

      20.5. Johnson & Johnson

      20.5.1. Company Overview

      20.5.2. Products And Services

      20.5.3. Business Strategy

      20.5.4. Financial Overview

      20.6. Amgen Inc.

      20.6.1. Company Overview

      20.6.2. Products And Services

      20.6.3. Business Strategy

      20.6.4. Financial Overview

      21. Key Mergers And Acquisitions In The Cancer Monoclonal Antibodies Market

      21.1. Ecolab Inc. To Acquire Purolite

      21.2. Exelixis Inc. Acquired Gamamabs Pharma SA’s AMHR2 Antibody Technology

      21.3. Sanofi Acquired Kymab Group Ltd.

      21.4. Boehringer Ingelheim Acquired Preclinical Antibody Pipeline From Northern Biologics Inc.

      21.5. Servier Acquired Symphogen A/S

      21.6. Gilead Sciences Acquired Forty Seven

      21.7. True North Acquired Stake In Biocon Biologics

      21.8. Catalent Inc. Acquired Bristol Myers Squibb’s Oral Dose Manufacturing Facility

      21.9. Bristol Myers Acquired Celgene

      22. Cancer Monoclonal Antibodies Market Opportunities And Strategies

      22.1. Global Cancer Monoclonal Antibodies Market In 2025 – Countries Offering Most New Opportunities

      22.2. Global Cancer Monoclonal Antibodies Market In 2025 – Segments Offering Most New Opportunities

      22.3. Global Cancer Monoclonal Antibodies Market In 2025 – Growth Strategies

      22.3.1. Market Trend Based Strategies

      22.3.2. Competitor Strategies

      23. Cancer Monoclonal Antibodies Market, Conclusions and Recommendations

      23.1. Conclusions

      23.2. Recommendations

      23.2.1. Product

      23.2.2. Place

      23.2.3. Price

      23.2.4. Promotion

      23.2.5. People

      24. Appendix

      24.1. Market Data Sources

      24.2. Research Methodology

      24.3. Currencies

      24.4. Research Inquiries

      24.5. The Business Research Company

      24.6. Copyright and Disclaimer

    List Of Tables

      Table 1: Global Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
    • Table 2: Global Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 3: Global Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 4: Global Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 5: Global Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 6: Global Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 7: Global Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 8: Global Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 9: Global Cancer Monoclonal Antibodies Market, By Region, Historic and Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 10: Global Cancer Monoclonal Antibodies Market, By Region, Historic and Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 11: Global Cancer Monoclonal Antibodies Market, By Country, Historic and Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 12: Global Cancer Monoclonal Antibodies Market, By Country, Historic and Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 13: Asia Pacific GDP Per Capita, 2015-2020, $
    • Table 14: Asia Pacific, Population By Age Group, By Country, 2015-2023, Thousands
    • Table 15: Asia Pacific Cancer Prevalence, Estimated Average Expenditure, 2019, $
    • Table 16:  Asia-Pacific Oncology Drugs Market, 2015-2025, $Billion
    • Table 17: Asia-Pacific Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
    • Table 18: Asia-Pacific Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 19: Asia-Pacific Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 20: Asia-Pacific Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 21: China GDP Per Capita, 2015-2020, $
    • Table 22: China, Population By Age Group, 2015-2023, Thousands
    • Table 23: China Cancer Prevalence, Estimated Average Expenditure, 2019, $
    • Table 24:  China Oncology Drugs Market, 2015-2025, $Billion
    • Table 25: China Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
    • Table 26: China Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 27: China Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 28: China Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 29: India Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
    • Table 30: India Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 31: India Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 32: India Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 33: Japan Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
    • Table 34: Japan Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 35: Japan Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 36: Japan Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 37: Australia Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
    • Table 38: Australia Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 39: Australia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 40: Australia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 41: Indonesia Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
    • Table 42: Indonesia Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 43: Indonesia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 44: Indonesia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 45: South Korea Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
    • Table 46: South Korea Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 47: South Korea Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 48: South Korea Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 49: Western Europe GDP Per Capita, 2015-2020, $
    • Table 50: Western Europe Population By Age Group, By Country, 2015-2023, Thousands
    • Table 51: Western Europe Estimated Average Expenditure, Cancer Prevalence, 2019
    • Table 52:  Western Europe Oncology Drugs Market, 2015-2025, $Billion
    • Table 53: Western Europe Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
    • Table 54: Western Europe Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 55: Western Europe Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 56: Western Europe Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 57: UK Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
    • Table 58: UK Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 59: UK Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 60: UK Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 61: Germany Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
    • Table 62: Germany Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 63: Germany Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 64: Germany Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 65: France Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
    • Table 66: France Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 67: France Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 68: France Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 69: Eastern Europe GDP Per Capita, 2015-2020, $
    • Table 70: Eastern Europe Population By Age Group, By Country, 2015-2023, Thousands
    • Table 71: Eastern Europe Estimated Average Expenditure, Cancer Prevalence, 2019
    • Table 72:  Eastern Europe Oncology Drugs Market, 2015-2025, $Billion
    • Table 73: Eastern Europe Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
    • Table 74: Eastern Europe Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 75: Eastern Europe Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 76: Eastern Europe Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 77: Russia Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
    • Table 78: Russia Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 79: Russia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 80: Russia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 81: North America GDP Per Capita, 2015-2020, $
    • Table 82: North America Population By Age Group, By Country, 2015-2023, Thousands
    • Table 83: North America Estimated Average Expenditure, Cancer Prevalence, 2019
    • Table 84:  North America Oncology Drugs Market, 2015-2025, $Billion
    • Table 85: North America Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
    • Table 86: North America Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 87: North America Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 88: North America Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 89: USA GDP Per Capita, 2015-2020, $
    • Table 90: USA Population By Age Group, 2015-2023, Thousands
    • Table 91: USA Estimated Average Expenditure, Cancer Prevalence, 2019
    • Table 92:  North America Oncology Drugs Market, 2015-2025, $Billion
    • Table 93: USA Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
    • Table 94: USA Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 95: USA Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 96: USA Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 97: South America GDP Per Capita, 2015-2020, $
    • Table 98: South America Population By Age Group, By Country, 2015-2023, Thousands
    • Table 99: South America Estimated Average Expenditure, Cancer Prevalence, 2019
    • Table 100:  South America Oncology Drugs Market, 2015-2025, $Billion
    • Table 101: South America Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
    • Table 102: South America Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 103: South America Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 104: South America Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 105: Brazil Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
    • Table 106: Brazil Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 107: Brazil Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 108: Brazil Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 109: Middle East GDP Per Capita, 2015-2020, $
    • Table 110: Middle East Population By Age Group, By Country, 2015-2023, Thousands
    • Table 111:  Middle East Oncology Drugs Market, 2015-2025, $Billion
    • Table 112: Middle East Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
    • Table 113: Middle East Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 114: Middle East Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 115: Middle East Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 116: Africa GDP Per Capita, 2015-2020, $
    • Table 117: Africa Population By Age Group, By Country, 2015-2023, Thousands
    • Table 118:  Africa Oncology Drugs Market, 2015-2025, $Billion
    • Table 119: Africa Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
    • Table 120: Africa Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Table 121: Africa Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Table 122: Africa Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, $ Million
    • Table 123: Global Cancer Monoclonal Antibodies Market, Key Competitor Estimated Market Shares, 2020, Percentage (%)
    • Table 124: F. Hoffmann-La Roche Ltd – Financial Performance, 2016 – 2020, $ Billion
    • Table 125: Merck & Co., Inc. – Financial Performance, 2016 – 2020, $ Billion
    • Table 126: Bristol Myers Squibb Company – Financial Performance, 2016 – 2020, $ Billion
    • Table 127: Johnson & Johnson – Financial Performance, 2016 – 2020, $ Billion
    • Table 128: Amgen Inc. – Financial Overview, 2016 - 2020, $ Billion
    • Table 129: Global Cancer Monoclonal Antibodies Market Size Gain ($ Million), 2020 – 2025, By Country
    • Table 130: Global Cancer Monoclonal Antibodies Market Size Gain ($ Million), Segmentation By Monoclonal Antibody Therapies, 2020 – 2025
    • Table 131: Global Cancer Monoclonal Antibodies Market Size Gain ($ Million), Segmentation By Application, 2020 – 2025
    • Table 132: Global Cancer Monoclonal Antibodies Market Size Gain ($ Million), Segmentation By End User, 2020 – 2025
    • Table 133: Cancer Monoclonal Antibodies - Market Data Sources

    List Of Figures

      Figure 1: Global Cancer Monoclonal Antibodies Market Segmentation By Monoclonal Antibody Therapies
    • Figure 2: Global Cancer Monoclonal Antibodies Market Segmentation By Application
    • Figure 3: Global Cancer Monoclonal Antibodies Market Segmentation By End User
    • Figure 4: Global Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
    • Figure 5: Global Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 6: Global Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 7: Global Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 8: Global Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 9: Global Cancer Monoclonal Antibodies Market, By Region, Historic and Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 10: Global Cancer Monoclonal Antibodies Market, By Country, Historic and Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 11: Asia-Pacific Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
    • Figure 12: Asia-Pacific Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 13: Asia-Pacific Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 14: China Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
    • Figure 15: China Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 16: China Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 17: India Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
    • Figure 18: India Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 19: India Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 20: Japan Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
    • Figure 21: Japan Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 22: Japan Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 23: Australia Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
    • Figure 24: Australia Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 25: Australia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 26: Indonesia Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
    • Figure 27: Indonesia Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 28: Indonesia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 29: South Korea Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
    • Figure 30: South Korea Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 31: South Korea Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 32: Western Europe Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
    • Figure 33: Western Europe Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 34: Western Europe Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 35: UK Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
    • Figure 36: UK Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 37: UK Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 38: Germany Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
    • Figure 39: Germany Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 40: Germany Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 41: France Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
    • Figure 42: France Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 43: France Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 44: Eastern Europe Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
    • Figure 45: Eastern Europe Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 46: Eastern Europe Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 47: Russia Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
    • Figure 48: Russia Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 49: Russia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 50: North America Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
    • Figure 51: North America Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 52: North America Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 53: USA Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
    • Figure 54: USA Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 55: USA Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 56: South America Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
    • Figure 57: South America Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 58: South America Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 59: Brazil Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
    • Figure 60: Brazil Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 61: Brazil Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 62: Middle East Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
    • Figure 63: Middle East Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 64: Middle East Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 65: Africa Cancer Monoclonal Antibodies Market, Historic, 2015 – 2020, $ Million
    • Figure 66: Africa Cancer Monoclonal Antibodies Market, Forecast, 2020 – 2025, 2030F, $ Million
    • Figure 67: Africa Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic And Forecast, 2015 – 2020, 2025F, 2030F, %
    • Figure 68: Global Cancer Monoclonal Antibodies Market, Key Competitor Estimated Market Shares, 2020, Percentage (%)
    • Figure 69: F. Hoffmann-La Roche Ltd – Financial Performance, 2016 – 2020, $ Billion
    • Figure 70: Merck & Co., Inc. – Financial Performance, 2016 – 2020, $ Billion
    • Figure 71: Bristol Myers Squibb Company – Financial Performance, 2016 – 2020, $ Billion
    • Figure 72: Johnson & Johnson – Financial Performance, 2016 – 2020, $ Billion
    • Figure 73: Amgen Inc. – Financial Overview, 2016 – 2020, $ Billion

    The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth

    Read More

    The Plasma Fractionation Market Share, Market Size, And Growth Rate 2022

    Read More

    The Biosimilar Therapeutic Peptides Market Share, Market Size, And Growth Rate 2022

    Read More

    Global Anticoagulants Market 2022 – Market Opportunities And Strategies

    Read More

    Latest Digestive Health Supplements Market Growth Study 2022-2026 By The Business Research Company

    Read More

    The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth

    Read More

    The Business Research Company offers the biosimilars market research report 2022 with industry size, share, segments and market growth

    Read More

    The Business Research Company offers the high potency apis market research report 2022 with industry size, share, segments and market growth

    Read More

    CAR-T Therapy Market 2021 - By Target Antigen (CD19, CD22, BCMA), By Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma), And By Region, Opportunities And Strategies – Global Forecast To 2030

    View Report

    Central Nervous System Drugs Market 2021 - By Type (Multiple Sclerosis (MS), Anti-Psychotic, Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics, Anti-Depressants, Other CNS Drugs), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies/ Drug Stores), By Route Of Administration (Oral, Intravenous, Intranasal/ Inhalation), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Over-The-Counter Drugs, Prescription-Based Drugs), And By Region, Opportunities And Strategies – Global Forecast To 2030

    View Report

    Oral Biologics & Biosimilar Drugs Global Market Report 2024 – By Therapy (Lymphocyte Modulators, Interleukin Inhibitors, Tumor Necrosis Factor-Alpha Inhibitors), By Disease (Asthma, Crohn's Disease, Carcinoma, Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Sarcoma, Psoriasis and Others), By Molecule Type (Vaccines, Proteins & Peptides, Monoclonal Antibodies, Other Molecule Types), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2024-2033

    View Report

    Cellular Immunotherapy Global Market Report 2024 – By Therapy (Tumor-Infiltrating Lymphocyte (TIL) Therapy, Engineered T Cell Receptor (TCR) Therapy, Chimeric Antigen Receptor (CAR) T Cell Therapy, Natural Killer (NK) Cell Therapy), By Primary Indication (B-cell Malignancies, Prostate Cancer, Renal Cell Carcinoma, Liver Cancer, Non-Hodgkin lymphoma, Other Primary Indications), By Application (Prostate Cancer, Breast Cancer, Skin Cancer, Ovarian Cancer, Brain Tumor, Lung Cancer, Other Applications ) – Market Size, Trends, And Global Forecast 2024-2033

    View Report

    Protein Inhibitors Global Market Report 2024 – By Product (Protein Kinase Inhibitors, Monoclonal Antibody, Other Products), By Application (Oncology, Inflammatory Diseases, Other Applications), By Distribution Channel (Hospital Pharmacies, Independent Pharmacies, Online Pharmacies ) – Market Size, Trends, And Global Forecast 2024-2033

    View Report

    Digestive Enzymes Global Market Report 2024 – By Enzyme Type (Carbohydrates, Protease, Lipase, Other Enzyme Types), By Origin (Animal, Fungi, Microbial, Plant), By Application (Indigestion, Chronic Pancreatitis, Irritable Bowel Syndrome, Other Applications), By Distribution Channel (Retail Stores, Online Stores) – Market Size, Trends, And Global Forecast 2024-2033

    View Report

    Oncology Biosimilars Global Market Report 2024 – By Drug Type (Monoclonal Antibody, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF)), By Cancer Type (Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, Other Cancer Types), By Distribution Type (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Market Size, Trends, And Global Forecast 2024-2033

    View Report

    Corticosteroids Global Market Report 2024 – By Product (Glucocorticoids, Mineralocorticoids), By Application (Skin Allergies, Rheumatology Indications, Endocrinology, Acute Respiratory Diseases, Other Applications), By End User (Hospitals, Clinics, Research Institutes, Other End Users) – Market Size, Trends, And Global Forecast 2024-2033

    View Report

    Frequently Asked Questions

    What is the definition of the cancer monoclonal antibodies market?

    Cancer monoclonal antibodies refer to a particular class of protein created in a lab that has the ability to bind to certain bodily targets, such as antigens on the surface of cancer cells. Each monoclonal antibody is designed to bind to a single antigen, and there are many different types of monoclonal antibodies. For further insights on the cancer monoclonal antibodies market, request a sample here

    How will the cancer monoclonal antibodies market drivers and restraints affect the cancer monoclonal antibodies market dynamics? What forces will shape the cancer monoclonal antibodies industry going forward?

    The cancer monoclonal antibodies market growth is aided by rise in the number of cancer cases across the globe. However, some cancer monoclonal antibodies market restraints include high costs involved in the development of monoclonal antibodies with advanced techniques. For further insights on the cancer monoclonal antibodies market, request a sample here

    What is the forecast market size or the forecast market value of the cancer monoclonal antibodies market?

    The cancer monoclonal antibodies market is expected to reach $98.11 billion in 2027 at a rate of 12.0%. For further insights on the cancer monoclonal antibodies market, request a sample here

    How is the cancer monoclonal antibodies market segmented?

    The global cancer monoclonal antibodies market is segmented as
    1) By Monoclonal Antibody Therapies: Bevacizumab (Avastin), Rituximab (Rituxan), Trastuzumab (Herceptin), Cetuximab (Erbitux), Panitumumab (Vectibix), Other Monoclonal Antibody Therapies
    2) By Application: Breast Cancer, Blood Cancer, Liver Cancer, Brain Cancer, Colorectal Cancer, Other Applications
    3) By End User: Hospitals And Clinics, Research Laboratories, Pharmacies, Other End Users
    For further insights on the cancer monoclonal antibodies market,     request a sample here

    Which region has the largest share of the cancer monoclonal antibodies market? What are the largest region's market size and growth rate?

    North America was the largest region in the cancer monoclonal antibodies market in 2022. For detailed insights on the largest region's market size and growth rate, request a sample here.

    Who are the major players in the cancer monoclonal antibodies market?

    Key competitors in the cancer monoclonal antibodies market are, Amgen, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Genmab AS, GlaxoSmithKline, Johnson & Johnson, Novartis AG, Merck & Co., Spectrum Pharmaceuticals, Seattle Genetics, Pfizer, Sanofi, Abbvie,  Takeda Pharmaceuticals, Genentech,  AstraZeneca,  Biogen. For further insights on the cancer monoclonal antibodies market, request a sample here.

    What are the key trends in the cancer monoclonal antibodies market?

    Major trends influencing the cancer monoclonal antibodies market include increasing product innovation through strategic collaborations. To sustain themselves in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with academic and research institutions in this market by way of partnerships and in- or out-licensing deals, this trend has been increasing over the past few years. For further insights on the cancer monoclonal antibodies market, request a sample here.

    What are the major opportunities in the cancer monoclonal antibodies market? What are the strategies for the cancer monoclonal antibodies market?

    For detailed insights on the major opportunities and strategies in the cancer monoclonal antibodies market, request a sample here.

    How does the cancer monoclonal antibodies market relate to the overall economy and other similar markets?

    For detailed insights on cancer monoclonal antibodies market's relation to the overall economy and other similar markets, request a sample here.

    What are the latest mergers and acquisitions in the cancer monoclonal antibodies industry?

    For detailed insights on the mergers and acquisitions in the cancer monoclonal antibodies industry, request a sample here.

    What are the key dynamics influencing the cancer monoclonal antibodies market growth? SWOT analysis of the cancer monoclonal antibodies market.

    For detailed insights on the key dynamics influencing the cancer monoclonal antibodies market growth and SWOT analysis of the cancer monoclonal antibodies industry, request a sample here.